Manager Ex-vivo, Translational Oncology Solutions Jobs in Rockville, MD at Champions Oncology
Title: Manager Ex-vivo, Translational Oncology Solutions
Company: Champions Oncology
Location: Rockville, MD
Salary: $200K – $250K*
Category: Pharmaceuticals & Biotech
Champions Oncology, Inc. provides an end-to-end range of research and development solutions and services that improve the productivity of oncology drug development. Usingin vitro,in vivoandin silicotesting platforms, biopharma can leverage the experience and expertise at Champions Oncology to help guide decision making for effective therapeutic development.
As the Ex-vivo Manager you will oversee the translational oncology Ex-Vivo team. You will be leading the pre-clinical/ex-vivo pipeline as well as the team’s deliverables including timelines, reports and metrics. This position involves lab-directed efforts and interactions with both internal and external partners to advance and oversee existing and future studies, co-develop new assays and grow the Champion’s Ex-Vivo program. This is an opportunity to serve as a scientific technical expert to internal team members, pharmaceutical and biotech companies on the utilization of the Champions TumorGraft and ImmunoGraft platforms intranslation oncology studies. Additional duties and responsibilities include, but are not limited to;
Manage and lead the Ex-vivo team to execute multiple tasks independently. Actively involved communication with clients and other departments within organization, including project management team, sales and marketing.
Responsible for creating new technology platforms and advancing the team processes to match growing demands
Maintains quality service by enforcing quality and customer service standards, analyzing and resolving quality and customer service problems, and establishing system improvements.
Communicate cross-functionally and serve as scientific technical expert on preclinical use of Tumorgraft platform.
Co-develop new preclinical models in support of Champions business platforms, including the organoid platform.
Accomplishes department objectives by managing staff; planning and evaluating department activities.
Develops, manages and reports strategic goals with clear metrics that reflect the business needs.
Monitor revenue recognition and adherence to estimates on quarterly revenue predictions as well as controlling expenses and budgets.
Supporting problem resolution and decision-making with positive can-do attitude
Work cross-functionally with other Champions departments to provide excellent client focused service that is quality and timeline driven
Qualifications and Skills
Ph.D. or M.D. in cancer biology, immunology, pharmacology, medicine or related discipline (highly preferred)
>10 years of research experience in in vitro cancer biology, and with extensive cell based assays and high throughput screening. Broad knowledge in molecular biology, cell biology and drug discovery
Industry experience in project planning, management and reporting is required. Effective manager with extensive experience of supervision and organization.
Expertise in immunology and/or immuno-oncology is desired
Excellent verbal and written communication skill in English.
Strong scientific leadership, with proven record of publications, presentations and problem solving ability.
Experience in preclinical ex-vivo high throughput studies preferred.
Demonstrated ability to work effectively and productively in a team-oriented environment while maintaining a strong sense of integrity and confidentiality.
Possess creative problem solving skills and the ability to exercise sound and accurate judgment in…
About Champions Oncology
Champions Oncology is an American technology company that develops mouse avatars. Called TumorGrafts, they are used to test a panel of chemotherapy regimens, targeted therapies and monoclonal antibodies to identify potential therapeutic options for cancer patients. The company was founded in 2007 by David Sidransky, M.D., a Johns Hopkins oncologist that was named by TIME as one of the top physicians and scientists in the United States in 2001. Champions TumorGrafts maintain the microenvironment surrounding the tumor and have been shown to have high correlation to the patient’s tumor. Due to this close resemblance to the human tumor, TumorGrafts are highly predictive of treatment outcomes in patients. Studies have shown the mouse avatars predict clinical benefit in 80% of patients. Approximately 450 TumorGrafts have been established as of April 2014. TumorGrafts are also being used as a pre-clinical research tool to improve clinical drug development. Compared to traditional xenograft models, TumorGrafts, have a greater degree of accuracy in predicting clinical effectiveness of oncology drugs and thus can decrease clinical risk for drug developers. Champions has formed partnerships with multiple drug developers, including Teva and Pfizer.